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Mitochondria continually undergo fusion and fission, and these dynamic processes play a major role in regu-
lating mitochondrial function. Studies of several genes associated with familial Parkinson’s disease (PD) have
implicated aberrant mitochondrial dynamics in the disease pathology, but the importance of these processes in
dopaminergic neurons remains poorly understood. Because the mitofusins Mfn1 and Mfn2 are essential for
mitochondrial fusion, we deleted these genes from a subset of dopaminergic neurons in mice. Loss of Mfn2
results in a movement defect characterized by reduced activity and rearing. In open field tests, Mfn2 mutants
show severe, age-dependent motor deficits that can be rescued with L-3,4 dihydroxyphenylalanine. These
motor deficits are preceded by the loss of dopaminergic terminals in the striatum. However, the loss of dopa-
minergic neurons in the midbrain occurs weeks after the onset of these motor and striatal deficits, suggesting
a retrograde mode of neurodegeneration. In our conditional knockout strategy, we incorporated a mitochond-
rially targeted fluorescent reporter to facilitate tracking of mitochondria in the affected neurons. Using an
organotypic slice culture system, we detected fragmented mitochondria in the soma and proximal processes
of these neurons. In addition, we found markedly reduced mitochondrial mass and transport, which may con-
tribute to the neuronal loss. These effects are specific for Mfn2, as the loss of Mfn1 yielded no corresponding
defects in the nigrostriatal circuit. Our findings indicate that perturbations of mitochondrial dynamics can
cause nigrostriatal defects and may be a risk factor for the neurodegeneration in PD.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative movement dis-
order characterized by resting tremor, rigidity, bradykinesia and
postural instability. PD symptoms are classically attributed to
dopamine depletion and the degeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNc).
However, additional neuronal circuits are affected, and
non-motor symptoms are often present, suggesting a systemic
pathology. There is compelling evidence that mitochondrial
dysfunction is a primary event in the disease process. Decreased
mitochondrial electron-transport chain activity has been
detected in tissues from PD patients (1,2), and toxins that
inhibit mitochondrial respiration can give rise to parkinsonism
in humans and animal models (3,4). The most direct evidence,
however, has come from the study of genes associated with fa-
milial forms of PD. Disruption of the PD-associated genes
PINK1, Parkin, DJ-1 or LRRK2 results in mitochondrial
defects and aberrant mitochondrial morphology (5–10).
Fusion and fission are fundamental processes that control
the function of mitochondria (11). Mitofusins Mfn1 and
Mfn2 are outer membrane GTPases that mediate the fusion
of mitochondrial outer membranes. The optic atrophy
protein OPA1 is necessary for the fusion of the mitochondrial
inner membranes. The dynamin-related protein Drp1 mediates
the opposing process of mitochondrial fission. Several neuro-
degenerative diseases, including PD, have been linked to per-
turbations in mitochondrial dynamics (12).
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Recently, this link has been strengthened by the analysis of
genes that cause familial forms of PD. The PINK1/Parkin
pathway is profoundly affected by mitochondrial fusion and
fission. In Drosophila, PINK1 and Parkin loss-of-function
mutants have severe mitochondrial defects, characterized by
swollen mitochondria with abnormal cristae (6–8,13). These
mitochondrial perturbations lead to the dysfunction of the indir-
ect flight muscles. The defects in mitochondria and muscle are
efficiently rescued by the overexpression of Drp1 or the knock-
down of Marf (a fly ortholog of mitofusin) or OPA1 (14–16).
In cultured mammalian cells, the PINK1/Parkin pathway has
been shown to promote the elimination of dysfunctional mito-
chondria by the autophagy machinery. This degradative
process, termed mitophagy, is dependent on mitochondrial
fission (17,18). Disruption of DJ-1 function causes mitochon-
drial fragmentation and enhanced sensitivity to oxidative
stress (5,9,19,20). The overexpression of PINK1 and Parkin
in DJ-1-deficient cells rescues the fragmented mitochondrial
morphology, suggesting the regulation of mitochondrial dynam-
ics by each pathway (5,20). Finally, PD-associated mutations of
LRRK2 in cells induce mitochondrial fragmentation and
increased localization of Drp1 to the mitochondria (10).
These observations indicate that PD-related mutations and
mitochondrial dynamics have a reciprocal relationship.
PD-related mutations can perturb mitochondrial dynamics,
and the consequences of these mutations can be modulated
by mitochondrial dynamics. These results highlight the need
to understand the function of mitochondrial dynamics in dopa-
minergic neurons. To address this issue, we have analyzed the
consequences of removing the mitofusins from dopaminergic
neurons. We find that the loss of Mfn2 results in a severe
movement disorder attributed to the progressive degeneration
of the nigrostriatal circuit.
RESULTS
Deletion of mitofusins from dopaminergic neurons
We utilized a genetic approach to assess the role of mitochon-
drial fusion in dopaminergic neurons. Mfn1 and Mfn2 condi-
tional knockout mice were crossed to the Slc6a3-Cre driver
(21), in which the endogenous dopamine transporter locus
expresses Cre recombinase in the A8–A10 subset of dopamin-
ergic neurons, including those of the SNc (Fig. 1A). Our mating
scheme also incorporated a mito-Dendra2 Cre reporter for the
dual purpose of labeling mitochondria and monitoring Cre-
dependent excision. Mice with the disruption of Mfn1 show
no phenotype up to 1 year of age (Supplementary Material,
Fig. S1). In contrast, mice with the disruption of Mfn2 are
hunched and hypoactive by 5 weeks of age when compared
with wild-type or heterozygous Mfn2 littermates. These mice
also exhibit kyphosis and reduced activity (Fig. 1B and Supple-
mentary Material, Movie S1). Weight gain is stagnant after 4
weeks of age, resulting in an increasingly larger weight differ-
ence between mutant and control littermates (Fig. 1C).
In our initial cohort of Mfn2 mutants, many animals died at
6–7 weeks of age due to apparent malnutrition. Mutant
animals (n ¼ 15) died or were culled due to significant
weight loss between 36 and 48 days of age. However, when
supplied with hydrated gel packs and crushed pieces of
regular chow on the cage floor, all mutant Mfn2 mice
survive beyond 6 months, with a majority surviving past 1
year of age. These mice likely have difficulty accessing food
and water in normal cages due to a severe rearing defect
(see later). In this respect, our mice are distinct from some
other dopamine depletion models that exhibit aphagia and
adipsia even when food is placed nearby (22,23). To minimize
possible secondary effects due to malnutrition, the phenotypic
analyses reported below were performed using mutant and
control mice provided with this dietary supplementation.
Movement disorder in Mfn2 mutants
Because initial observations suggested that Mfn2 mutant mice
had reduced activity, we monitored their spontaneous move-
ments in a longitudinal open field study. Mfn2 mutant mice
show an age-dependent decline in locomotive activity
(Fig. 2A). At 4–5 weeks, mutant animals travel only 68% of
the distance traversed by wild-type control animals. This
defect progresses over the next several weeks. By 8–11
weeks of age, the distance traveled by mutants reduces to
34% of wild-type controls (Fig. 2B). In contrast, Mfn2 hetero-
zygous animals show normal locomotion. We compared
the Mfn2 homozygotes to both wild-type controls and hetero-
zygous controls carrying Slc6a3-Cre, because the knock-in
Cre allele causes a slight, non-significant, decrease in dopa-
mine transporter levels in the heterozygous state (21). We
found that Mfn2 heterozygotes carrying Slc6a3-Cre are
Figure 1. Growth defect in Mfn2 mutant mice. (A) Mating scheme.
Slc6a3-Cre is controlled by the dopamine transporter locus and is expressed
in a subset of dopaminergic neurons, particularly the SNc, VTA and retroru-
bral field (21). The cross also incorporated a cre-induced, mitochondrially tar-
geted Dendra2 (termed PhAM). (B) Representative image of a 22-week-old
Mfn2 mutant (KO) compared with a heterozygous littermate (Het). Note the
small size and severe kyphosis of the Mfn2 mutant mice. (C) Plot showing
weekly weight measurements. Each point represents the average weight+
SEM (n ¼ 10–15 for each genotype and sex). Both male and female Mfn2
mutants are significantly smaller (P , 0.05, two-tailed Student’s t-test) than
control animals by 5 weeks of age.
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indistinguishable from wild-type controls in all the assays used
in this study.
Similar to travel distance, the speed of movement exhibited
by Mfn2 mutant mice declines with age (Fig. 2C). We also
observed a strong rearing defect in mutant Mfn2 mice that is
present as early as 4 weeks of age (Fig. 2D and Supplementary
Material, Movie S1). This postural defect likely contributes to
the starvation and dehydration observed at 6 weeks when
cages are not supplemented with food and gel packs on the
floor. Consistent with the decreased locomotion, Mfn2 mutants
spend twice as much time inactive at 6–7 weeks of age. By
8–11 weeks, this discrepancy increases to 6-fold (Fig. 2E). Of
note, the locomotive defect is specific for Mfn2 mutants; Mfn1
mutants show no motor deficiency in the open field test
(Supplementary Material, Fig. S1). Moreover, the double
Mfn1/Mfn2 mutants do not have an exacerbated phenotype com-
pared with Mfn2 mutants (Supplementary Material, Fig. S2).
Overall, measurements from the open field test suggest that, be-
ginning at 4–5 weeks, Mfn2 mutants exhibit progressive brady-
kinesia and a postural defect, both cardinal signs of PD.
Retrograde degeneration of SNc dopaminergic neurons
To determine whether the motor deficits in mutant animals are
accompanied by a loss of dopaminergic innervation, we used
tyrosine hydroxylase (TH) immunoreactivity to assess the
nigrostriatal circuit. We first analyzed the striatum, the end-
point of the nigrostriatal pathway. Here, TH-staining marks
Figure 2. Longitudinal analysis of locomotive activity in Mfn2 mutants. (A) Representative traces from open field analysis. The traces represent spontaneous
movement in an open field during a 15-min observation period. The genotypes and ages of the mice are indicated. The open field analysis was quantified to obtain
the (B) distance traversed, (C) average velocity, (D) rearing frequency and (E) immobile periods between activities. In all graphs, values from the heterozygous
and homozygous animals were normalized to that of the wild-type controls, and error bars represent the propagated standard error. The Student’s t-test was used
to obtain P-values between Mfn2 mutants and wild-type controls (∗P , 0.05; ∗∗P , 0.001; n ¼ 6–10 animals per age and genotype).
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the axon terminals derived from the SNc. In Mfn2 mutants, the
striatum shows a 25% reduction in dopaminergic terminals at
3 weeks of age (Fig. 3A and C). Loss of TH immunoreactivity
is detected first in the dorsolateral striatum (Fig. 3A, outlined
region in a 3-week sample) and gradually encompasses the
entire striatum by 11 weeks. Interestingly, the regional sever-
ity of striatal loss in Mfn2 mutants resembles the pattern
described in PD patients (24,25). By 8–10 weeks, the deple-
tion of dopaminergic terminals increases to 76% in Mfn2
mutant animals (Fig. 3C). In contrast, the projections to the
nucleus accumbens (NAc) and olfactory tubercle (OT), which
come from dopaminergic neurons in the ventral tegmental area
(VTA), appear to be more protected. These dopaminergic term-
inals, which are part of the mesolimbic pathway, are moderately
preserved at 11–14 weeks (Fig. 3A, outlined regions in the 11
and 14 week panels).
Moving upstream in the nigrostriatal circuit, we counted the
number of TH-immunoreactive neurons in the SNc. In contrast
Figure 3. Retrograde degeneration of SNc dopaminergic neurons. (A) Dopaminergic projections to the striatum (Str), NAc and OT. The diagram delineates these
regions. Sections were stained with TH antibody to label dopaminergic projections (brown pigment). At 3 weeks of age, Mfn2 mutant animals show decreased
TH-immunoreactive terminals in the dorsolateral striatum (outlined region). Later time points reveal widespread loss in the striatum. VTA projections to the NAc
and OT are still present, albeit reduced, at 11 and 14 weeks (outlined regions in bottom two panels). (B) Dopaminergic neurons at the SNc and VTA. Sections of
the midbrain were stained with TH and counterstained with Cresyl violet (blue) to identify dopaminergic neurons. At 11 and 14 weeks, the Mfn2 mutants exhibit
reduced staining in the SNc, whereas the VTA is relatively preserved. The SNc and VTA regions are outlined. (C) Quantification of TH-staining. Measured
values of the TH-positive signal from heterozygous and homozygous animals were normalized to wild-type controls. For each animal, three sections were mea-
sured. The Student’s t-test was used to obtain P-values (∗P , 0.05; ∗∗P, 0.001; n ¼ 3–6), and the error bars represent the propagated error. (D) Quantitation of
dopaminergic cell loss in the SNc. Counts from heterozygous and homozygous animals were normalized to wild-type controls (n ¼ 3 for each genotype). For
each animal, nine sections spanning the rostro-caudal extent of the midbrain were manually counted. Statistical analysis was performed as in (C). (E) Magnified
images of (B) showing the loss of dopaminergic neurons and processes in Mfn2 mutant animals.
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to the striatum, there is no notable loss of TH-positive neurons
in the SNc at either 3 or 8–9 weeks (Fig. 3B and D). The earli-
est time point with neuronal loss occurs at 10–12 weeks, with
a 52% decrease in TH-immunopositive neurons. Further de-
generation followed at subsequent ages (Fig. 3D). Additional-
ly, the neurons remaining in Mfn2 mutants appear to have
smaller cell bodies as well as diminished neuronal processes
(Fig. 3E). Partial loss of neurons was also observed at the
VTA but not to the extent of the SNc.
Because degenerating neurons can lose the expression of
neuronal markers, the loss of TH immunoreactivity does not
necessarily indicate neuronal loss. To directly evaluate the
loss of neurons, we performed Nissl staining of the SNc
(Fig. 4). Normal staining was observed at 3 weeks of age,
but by 11 weeks and beyond, the SNc showed a reduced
density of Nissl-stained cells. Taken together, these results in-
dicate two pertinent features of neurodegeneration in this
mouse model. First, multiple types of dopaminergic neurons
have a requirement for Mfn2, but the nigrostriatal circuit exhi-
bits enhanced vulnerability compared with the mesolimbic
pathway. Likewise, SNc neurons in PD patients are more se-
verely affected than the VTA population (26,27). Second,
the degeneration of Mfn2-deficient dopaminergic neurons
occurs in a stepwise manner. The initial defects appear at
the axon terminals, followed 1–2 months later by the degen-
eration of the cell bodies.
Mitochondrial fragmentation and depletion in
dopaminergic neurons
We previously generated a Cre reporter of mitochondrial dy-
namics that targets the photo-convertible fluorescent protein
Dendra2 to the mitochondrial matrix (28). The expression of
mito-Dendra2 relies on the Cre-mediated excision of an up-
stream loxP-flanked termination signal. In our mating
scheme (Fig. 1A), mito-Dendra2 expression depends on the
Slc6a3-Cre driver, thereby allowing us to visualize mitochon-
dria within the affected neurons, a key benefit in the densely
populated midbrain. We have also established a slice culture
system to assess mitochondrial dynamics in Mfn2-null dopa-
minergic neurons. The organotypic culture system has been
extensively used for the long-term assessment of neuronal
function and development in vitro because it preserves the
cyto-architecture and circuitry between multiple brain
regions (29,30). To best preserve the nigrostriatal connections,
we sectioned the brains at an angle previously characterized to
retain these projections (31,32).
In slice cultures from wild-type and heterozygous brains, we
found that Slc6a3-Cre/mito-Dendra2 expression is specific for
dopaminergic neurons, as evidenced by its restriction to cells
with TH immunoreactivity (Fig. 5A). The mitochondria in
control heterozygous slices have a mixed morphology
profile, consisting of both tubular structures in proximal pro-
cesses and short puncta in distal projections. In Mfn2-null
slices, we found swollen and fragmented mitochondria in the
soma and proximal processes. Consistent with our histological
analysis (Fig. 3E), the Mfn2 mutant neurons have fewer and
thinner processes extending from the cell body (Fig. 5A). In
addition, the Mfn2 mutant cultures contain many neurons
that express mito-Dendra2 but lack or have reduced TH
signal. The failure to maintain TH expression suggests that
these neurons are at an intermediate stage of degeneration
(Fig. 5A, starred neurons). We also noted a severe depletion
of mitochondria in neuronal processes both proximal and
distal to dopaminergic cell bodies (Fig. 5B). Mutant slices
show a 70% reduction in mitochondrial mass after normalizing
to mito-Dendra2-positive cell bodies (Fig. 5C). In contrast, slices
from Mfn1-null mice showed normal mitochondrial morphology
and density (Supplementary Material, Fig. S3A and B).
Decreased mitochondrial transport along nerve processes
in Mfn2 mutants
To monitor mitochondrial transport along dopaminergic axons
and dendrites, we performed live imaging of mito-Dendra2 in
the slice cultures. For accurate monitoring of mitochondrial
dynamics in the dense milieu of dopaminergic projections, we
photo-converted mitochondria in a nerve process and tracked
the movement of this labeled subpopulation (Fig. 6A, top).
From the time-lapse movies, we generated kymograph repre-
sentations that resolved the complex trajectories of the photo-
converted mitochondria (Fig. 6A, bottom). With a vertical
time axis, mobile mitochondria create diagonal tracks,
whereas stationary mitochondria project as vertical streaks.
Consistent with previous studies describing the mobility of
mitochondria in neuronal processes (33–35), we found that a
subpopulation of mitochondria is highly mobile in control dopa-
minergic neurons (Fig. 6A and Supplementary Material, Movie
S2). Mfn1-null neurons similarly contained a subpopulation of
highly mobile mitochondria (Supplementary Material,
Fig. S3C and D). In contrast, mitochondrial transport is
minimal in Mfn2-null neurons (Fig. 6B and Supplementary
Material, Movie S3). In heterozygous controls, 50% of photo-
conversion experiments resulted in at least one transport
event, defined as directed movement for 5 mm. In Mfn2
mutants, only 14% of photo-conversion experiments showed a
transport event (Fig. 6C). Additionally, mobile mitochondria
in Mfn2 mutant dopaminergic neurons exhibit more intermittent
movements and longer immobile periods. As a result, the
average velocity for mitochondria in Mfn2-null slices is also
slower relative to controls, 0.05 versus 0.15 mm/s (Fig. 6D).
Rescue of Mfn2 mutants with L-DOPA treatment
The reduced level of TH-positive terminals in Mfn2 mutant
mice implies a deficiency of dopamine in the striatum. We
therefore tested whether the administration of L-3,4 dihydroxy-
phenylalanine (L-DOPA) by peritoneal injection could alleviate
the motor defects of Mfn2 mutant mice. With 4–5- and 8–
9-week-old mice, we found that L-DOPA administration
causes a substantial increase in both the travel distance and
the rearing frequency of Mfn2 mutant mice (Fig. 7). Collective-
ly, these results suggest that dopamine deficiency, attributed to
axonal loss, underlies the motor deficits in Mfn2 mutants.
DISCUSSION
Several genes associated with familial PD—including PINK1,
Parkin, DJ-1 and LRRK2—have been linked to mitochondrial
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Figure 4. Loss of dopaminergic neurons in the SNc. Coronal midbrain slices were analyzed by fluorescent Nissl staining to highlight neurons. (A) The SNc is
indicated by the outlined oval. Decreased neuronal density in the SNc is apparent by 11 weeks in the Mfn2-null mutant. Scale bar is 100 mm. (B) High-
magnification images of Nissl-stained cells in the SNc. Scale bar is 20 mm.
Figure 5. Mitochondrial fragmentation and depletion in slice cultures of Mfn2 mutants. Cre-mediated expression of mito-Dendra2 labels dopaminergic neurons.
(A) Slice cultures of heterozygous controls and Mfn2 mutants. Slices were immunostained with TH (red). The first column shows a merged image of TH and
mito-Dendra2 fluorescence (green), while the last column is an enlargement of the boxed zone. The asterisks highlight degenerating Mfn2-null neurons that have
diminished or absent TH staining. (B) Mito-Dendra2 signal in neuronal projections. Marked depletion of mitochondria in both proximal and distal processes is
evident in Mfn2 mutant slices. (C) Quantification of mitochondrial mass normalized to the number of dopaminergic neurons. For each sample, the total
mito-Dendra2-positive area in a 5 mm × 5 mm region was measured and normalized to the number of Dendra2-positive neurons. Mitochondrial mass is reported
as the percentage area of heterozygous control+SEM. The Student’s t-test was used to evaluate statistical significance (∗∗P, 0.001; n ¼ 5 for mutant slices;
n ¼ 7 for control). Scale bar is 10 mm for all images.
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dynamics. As a result, we sought to understand the role of
mitochondrial dynamics in the nigrostriatal pathway. We
deleted the mitofusins Mfn1 and Mfn2 from a subset of dopa-
minergic neurons, including those of the SNc. Mfn2 mutants
exhibit severe locomotive defects, which are preceded by the
loss of dopaminergic efferents to the striatum. Importantly,
these mice show dysfunction in the striatum and motor deficits
weeks earlier than the loss of nigral neurons. This sequence of
pathological findings is consistent with retrograde degener-
ation, in which neuronal deficits initiate distally in the axon
terminals and progress backward to the cell bodies. Interest-
ingly, pathological studies of PD brains have suggested a
similar ‘dying back’ mode of neurodegeneration based on
the disproportionate loss of striatal dopamine relative to the
neuronal loss in the SNc (36,37). A recent mouse model of
PD with deletions in mitochondrial DNA (38) and administra-
tion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to rhesus
monkeys (39) also produces this differential pattern of neuron-
al damage.
We found that dopaminergic neurons lacking Mfn2 have a
prominent defect in mitochondrial content and transport in
neuronal processes. This latter observation supports growing
evidence that the mitofusins are important for mitochondrial
movement (40,41). Mechanistically, this link may be related
to the observation that Mfn2 can co-immunoprecipitate with
exogenously expressed Miro and Milton, which are important
components for kinesin-mediated transport of mitochondria
along microtubules (41). In contrast to the severe defects
found in Mfn2-null animals, we found that Mfn1-null mice
show no apparent movement disorder, and correspondingly,
no defects in the nigrostriatal circuit or in mitochondrial trans-
port. At present, it is unknown whether this distinction is
simply due to differential levels of these proteins in dopamin-
ergic cells or to functional differences between Mfn1 and
Mfn2 (42).
The identification of PD-related genes, such as a-synuclein,
PINK1, Parkin, DJ-1 and LRRK2, has led to the development
of numerous mouse models of PD. Although some of these
models show modest decreases in striatal dopamine and asso-
ciated motor impairments, they generally fail to recapitulate
the progressive loss of dopaminergic neurons that is the patho-
logical hallmark of PD (43,44). In contrast, disruption of mito-
chondrial function by the loss of mitochondrial transcription
factor A (Tfam) results in dopamine cell death that is asso-
ciated with reduced mitochondrial DNA content and severe re-
spiratory chain deficiency (45,46). In our study, we find that
dopaminergic neurons lacking the mitochondrial fusion gene
Mfn2 exhibit fragmented mitochondria that fail to be trans-
ported within the axon. An important feature of our mouse
model is the clear demonstration of progressive degeneration
Figure 6. Decreased mitochondrial transport in Mfn2 mutant cultures. (A) A representative tracking experiment of an Mfn2 heterozygous control. A subset of
mitochondria in the nerve process was photo-converted to red for time-lapse imaging. The images of the photo-converted signal were processed into a kymo-
graph to visualize mitochondrial movement (binary image). Velocity measurements were calculated from the red tracks that overlay mitochondrial trajectories.
(B) Representative tracking experiment in an Mfn2 mutant showing the loss of mitochondrial transport. (C) Quantification of mitochondrial transport in neuronal
processes. For each photo-conversion experiment, a positive event was defined as the directed movement of more than 5 mm during the 15 min recording session.
The graph shows the frequency of photo-conversion experiments that resulted in at least one positive event. For Mfn2 heterozygous slices, 150 experiments were
scored; for Mfn2 mutant slices, 138 experiments were scored. The Student’s t-test was used to calculate statistical significance (∗∗P , 0.001). (D) A scatter plot
of the average velocity of moving mitochondria. The red dots indicate the population averages+SD. Statistical significance was calculated as in (C) (n ¼ 138
mitochondria in heterozygous slices, n ¼ 38 mitochondria in mutant slices). Scale bar is 5 mm for all images.
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at the cellular level. Early deficits are regionally restricted to
the nerve terminals, and it takes 2 months to progress to neur-
onal cell loss. The time span between distal defects and cell
loss presents a window for investigating the cellular mechan-
isms leading to the degeneration of dopaminergic neurons.
MATERIALS AND METHODS
Generation of Mfn mutant mice
Conditional mouse lines of Mfn1 and Mfn2 have been described
previously (47). The Slc6a3-Cre driver was obtained from
the Jackson Laboratory (B6.SJL-Slc6a3tm1.1(cre)Bkmn/J).
All experiments were approved by the Caltech Institute
Animal Care and Use Committee.
Open field test
Animals were placed in a 50 cm × 50 cm white Plexiglass box
and allowed an adaptation period of 30–60 min prior to being
analyzed. Activity was recorded for two consecutive sessions,
each lasting 15 min, by a ceiling-mounted video camera. The
Ethovision software (Noldus, Leesburg, VA, USA) was used
to measure the distance, velocity, rearing frequency and im-
mobility of the mice.
In the L-DOPA experiments, animals were first injected
intraperitoneally with saline and monitored by open field ana-
lysis to obtain baseline activity. Subsequently, animals were
administered a cocktail of L-3,4-dihydroxyphenylalanine
methyl ester (25 mg/kg, Sigma) and the DOPA decarboxylase
inhibitor benserazide hydrochloride (5 mg/kg, Sigma). After
60 min, animals were followed by open field analysis.
Histological analysis
Animals were sacrificed after anesthesia with halothane.
Brains were dissected and fixed overnight at 48C in 10%
neutral buffered formalin. The caudal portions of the brains
were trimmed in an acrylic matrix (2 mm from the end)
before specimens were mounted and sectioned with the
Leica VT1200S vibratome. Brains were sliced into consecu-
tive sections of 50 mm for the striatum or 35 mm for the mid-
brain. For counting, every fourth midbrain slice was processed
for TH (1:1000, Chemicon) immunohistochemistry following
the manufacturer’s protocol (Vectastain elite ABC kit,
Vector Labs). To enhance antigenicity, slides were boiled
for 40 min in 10 mM sodium citrate buffered at pH 6. Sections
were developed with 3,3′-diaminobenzidine and subsequently
immersed in a 0.1% cresyl violet acetate solution for Nissl
counterstain. Each slide contained a set of homozygous, het-
erozygous and wild-type samples to minimize staining vari-
ability between samples. Two reviewers, blinded to the
genotypes, counted TH-immunoreactive and Nissl-positive
cells at 100× magnification. For each animal, nine sections
spanning the midbrain were counted. Total counts from the
heterozygotes and homozygotes were normalized to the age-
matched wild-type controls. Densitometry of the TH signal
in the striatum has been described (39). Briefly, the Nikon Ele-
ments software was used for computer-assisted measurement
of TH intensity in the striatal area. The same threshold was
maintained across all samples on the slide. For each animal,
three sections, spanning the rostral-caudal extent of the stri-
atum, were measured, summed and normalized to wild-type
measurements.
For fluorescent Nissl staining, sections were stained with
Nissl conjugated Alexa 633 (1:500, Molecular Probes) for
1 h at room temperature. Sections were rinsed with several
times with phosphate buffered saline prior to mounting with
Cytoseal.
Imaging and microscopy analysis
Images were acquired on a Zeiss LSM 710 confocal microscope
using EC-Plan-Neofluar 40×/1.3 oil or Plan-Apochromat
63×/1.4 oil objectives. Z-stack acquisitions oversampled
twice the thickness of the optical slice, and Zen 2009 analysis
software was used for maximum z-projections. To photo-
Figure 7. Increased motor activity after L-DOPA injection. Animals were analyzed by an open field test after a control saline injection to obtain baseline activity.
They were tested a second time after an L-DOPA injection. Quantification of open field data for total distance traveled (A) and rearing frequency (B). For each
animal, the activity after L-DOPA treatment was normalized to the activity after the saline injection. The Student’s t-test was used to obtain P-values (∗P, 0.05;
∗∗P , 0.001; n ¼ 10–15 per genotype), and error bars represent the propagated error.
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convert Dendra2, a small region was irradiated with the
405 nm laser (4% laser power) for 60 iterations at a scan
speed of 6.3–12.61 ms/pixel. For live imaging, slices were
submerged in Tyrode’s buffer (Sigma) supplemented with
25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
and 6.5 mg/ml of glucose and stabilized with a slice anchor
(Warner Instruments). Slices were imaged on a stage-top
heated platform maintained at 358C. Four fields were
imaged in each slice and time-lapse movies were acquired at
20 s intervals for 15 min. Custom macros were written for
ImageJ software to produce kymographs and to measure vel-
ocity traces. In quantifying mitochondrial area, noise reduction
in maximally z-projected images utilized the median and
Liptschitz top hat filters. Subsequently, the dynamic threshold-
ing plugin was applied to segment mitochondria, and the
‘Analyze particles’ algorithm in ImageJ provided the quantita-
tion of mitochondrial signal. Manual counts of
mito-Dendra2-positive cells in the z-stacks used the ‘Cell
counter’ algorithm.
Organotypic slice cultures
Preparations of sagittal organotypic slices have been described
(36). We made modifications to the angle of sectioning to
improve the preservation of nigrostriatal projections (32).
The rotating magnetic stage from the Leica VT1200S vibra-
tome was tilted so that sections could be acquired between
108 and 158 from the midline. Pups were sacrificed at postnatal
days 10–12. Typically, only two slices (one per hemisphere)
of 330 mm thickness contained the nigrostriatal pathway.
Slices acquired at 1–1.2 mm lateral from the midline were
retained for culturing. Cultures were fed three times a week
using the Stoppini media (37). Brain slices were equilibrated
in culturing conditions for at least 2 weeks prior to experimen-
tation. For immunofluorescence, membranes around the slices
were trimmed and fixed in 4% paraformaldehyde–lysine–
periodate overnight at 48C. Slices were permeabilized with
1% Triton X-100 for 30 min and incubated with blocking
buffer (2% goat serum, 1% bovine serum albumin and 0.1%
Triton X-100) for 4–6 h at room temperature. Samples were
incubated with anti-TH antibody overnight at 48C, followed
by secondary antibody (goat anti-rabbit IgG Alexa 568, Mo-
lecular Probes) for 2 h.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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